‘Green Gold' Review: How the Avocado Grew on Us
An odd quirk of the avocado, Persea americana to botanists, is the clockwork performed by its blossoms. They undergo a complicated sequence of opening, closing and reopening that keeps each flower's male and female sex organs from operating on the same day. Among two large categories of cultivated strains, group A trees bear flowers that are functionally female in the morning and male the next afternoon. Meanwhile, group B's flowers are female in the afternoon and male the next morning.
Unreliable pollination had long baffled commercial avocado growers until, on May 5, 1923, the botanist A.B. Stout had the game-changing idea of setting up cameras in a California orchard. His photographs solved the mystery by capturing the discrepancy between A and B's blossoming schedules, thus suggesting the wisdom of planting trees from both groups in close proximity.
The lesson doesn't seem to have great priority in today's industrial-scale avocado production, at least as depicted by Sarah Allaback and Monique F. Parsons in 'Green Gold,' a trenchant chronicle of the fruit's commercial and cultural exploitation from the late 19th century to the present. The authors' enlightening picture draws on a wide range of material—plant pathology studies, avocado-association yearbooks, Super Bowl commercials, leading figures' field notes and more.
The book broadly centers on two 'mother trees' while saluting 'the people who nurtured them, for money and love.' In 1911 Carl Schmidt, an American investigator scouting for avocado specimens in Mexico, observed a tree bearing splendid crops near Atlixco in Puebla state. He was sufficiently impressed to take cuttings from the tree and bring them back for grafting in an Altadena, Calif., nursery, where the strain received the varietal name El Fuerte (Spanish for 'the Strong One').
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform
Using AI machine learning, the Company discovers distinct biomarkers for detecting certain rare liver cancers that have stem cell characteristics and will include them as additional indications in its preclinical program Lehi, Utah, June 09, 2025 (GLOBE NEWSWIRE) -- CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body's immune system to treat cancer, today announced that it will expand its preclinical program to include liver cancers, specifically rare stem cell-like forms of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). Patients with these stem cell-like tumors have a significantly worse survival than patients with more traditional liver tumors. CancerVax's novel platform uses engineered lipid nanoparticles to detect and mark only cancer cells for destruction by the immune system. The nanoparticles use a 2-step detection mechanism to precisely target cancer cells, while leaving healthy cells unharmed. The nanoparticles first target cells with specific surface proteins ('Marker1'), then release proprietary Smart mRNAs that are activated only in the presence of cancer-specific signatures ('Marker2'). Once activated, the mRNA forces cancer cells to express proteins associated with well-immunized diseases like measles, effectively tricking the immune system into killing cancer cells as if they were common diseases. The Company previously announced that it was targeting pancreatic ductal adenocarcinoma (PDAC) in its preclinical program. After extensive research and AI-driven analysis, the Company's scientific team has discovered a very distinct Marker2 signature for a group of rare liver cancers. These tumors have stem cell characteristics, making them more aggressive and less responsive to traditional therapies. By taking advantage of the distinct Marker2 signature, CancerVax believes it can overcome the severe unmet clinical need for these cancer patients and can more quickly validate the universality of its platform. The Company's preclinical cancer indications will now be expanded to three (3) cancer types: PDAC, rare HCC and ICC. Dr. Adam Grant, Principal Scientist of CancerVax said, "When we first identified these subsets of liver cancers with this distinct Marker2 signature, I couldn't believe it. It was amazing to come across a patient population that has a high unmet clinical need and is uniquely suited to validate our technology. Of course, we expect that our platform will work on many different cancer types but the unique genetic signatures in these rare liver cancers make them a no-brainer for us to target. This precision-based discovery is what every computational biologist dreams of and I'm beyond excited to have the opportunity to help provide relief for these patients with severely poor outcomes. Dr. George Katibah, Chief Scientific Officer of CancerVax said, "The results from our AI data analytics are really striking. This particular cancer biology leads to not one but a group of rare liver cancers for which there are limited treatments. Our team has uncovered this novel cancer stem cell biology using advanced computational techniques showing that these tumors' underlying biology can be targeted by the CancerVax approach. These results demonstrate the flexibility of our platform and how we can swap out Marker1 and Marker2 to attack other cancers with a precision medicine approach. The next steps include creating new nanoparticles for these new cancer indications and to perform in vitro and in vivo studies to evaluate efficacy and safety.' The Company's universal cancer treatment platform is architected in such a way that off-the-shelf injections can be created by changing the Marker1 and Marker2 combination to target different cancer types. This approach allows for the Company's immunotherapies to be broadly available when a patient is diagnosed and needs to be treated immediately. These injections are more like 'off-the-shelf' flu shots, rather than complex treatment procedures. About CancerVax CancerVax is a pre-clinical biotech company developing a novel Universal Cancer Treatment platform that will be customizable, as an injection, to treat many types of cancer. Our innovative approach DETECTS, MARKS, and KILLS only cancer cells. By making cancer cells look like well-immunized common diseases such as measles or chickenpox, we intend to use the body's natural immune system to easily kill the cancer cells. We look forward to the day when treating cancer will be as simple as getting a shot -- a better way to fight cancer. To learn more, please visit Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results and financial condition may differ materially from those in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise. Press Contact:CancerVax, (805) 356-1810Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
28bio Announces Nexon™ Neurotechnology Platform Powered by Engineered Human Brains
Exhibits complex neurological processes—including memory, learning, and cognition—and predicts human outcomes in preclinical drug development NEW ORLEANS, June 9, 2025 /PRNewswire/ -- 28bio today announced the Nexon™ neurotechnology platform—a major advancement in understanding human brain function. The platform integrates tissue engineering, neural interfacing and AI to engineer human brains at-scale and replicate complex neurological processes. The Nexon™ platform is now being used to improve the prediction of therapeutic efficacy and toxicity in humans, with several of the world's largest pharma companies already integrating Nexon™ into their drug development workflows. The Nexon™ platform also incorporates Organoid Intelligence (OI). The growing field of OI combines human brain organoids with brain-machine interfaces to model memory, learning, and cognition in vitro, offering novel functional cognitive biomarkers with the potential to reshape drug development in neurodegenerative disorders including Alzheimer's disease. Neurological drug development faces some of the highest failure rates in the pharmaceutical industry, due to poor translatability of animal models. Despite promising preclinical study results, many therapies ultimately fail in humans—contributing to a growing neurological health crisis and need for more predictive, human-relevant models. "We engineer human brains capable of elucidating the complexity of neurological processes and produce predictive data needed to change the trajectory of neurological drug development," said Alif Saleh, CEO of 28bio. "Industry and regulators are urgently asking for solutions to develop better neurological drugs faster and cheaper." About 28bio28bio is a neurotechnology company engineering human brains at-scale exhibiting memory, learning, and cognitive functions. Its Nexon™ platform integrates tissue engineering, neural interfacing, and AI to reverse today's neurological health crisis by improving the ability to predict which therapies will work in humans. 28bio is committed to advancing ethical standards in the development of brain organoid technology and engineered human cognition. For more information, visit View original content to download multimedia: SOURCE 28bio Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the European Renal Association
EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of primary membranous nephropathy (pMN) and other autoimmune renal diseases, including IgA nephropathy (IgAN), minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and lupus nephritis (LN), offering treatment options for over 10 million patients worldwide. No drug has been approved globally for the treatment of pMN currently. There are approximately 2 million patients with pMN in China, and nearly 220,000 patients in the United States, Europe and Japan. As of December 17th, 2024, the ongoing Phase 1b/2a clinical trial of EVER001 includes longer-term data collected from some patients: 10 patients in the low-dose cohort completed 52 weeks of follow-up, and 10 patients in the high-dose cohort completed 24 weeks of treatment. Preliminary results showed that EVER001 was well-tolerated and effective in patients with pMN. These results support the potential of EVER001 as a treatment for proteinuric autoimmune glomerular diseases.- Compared to baseline, the least squares (LS) geometric mean levels of anti-PLA2R autoantibodies decreased by 62.1% in the low-dose cohort and 87.3% in the high-dose cohort at week 12. The reductions in both cohorts reached approximately 93% at week 24.- In the low-dose cohort, a 78.0% of reduction in proteinuria was observed by the end of 36 weeks of treatment. This reduction was sustained through week 52. In the high-dose cohort, a 70.1% of reduction in proteinuria at week 24 was shown.- EVER001 was generally safe and well tolerated. No clinically significant adverse events commonly associated with covalent irreversible BTK inhibitors were observed. SHANGHAI, June 9, 2025 /PRNewswire/ -- Everest Medicines (HKEX "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that positive results in the ongoing Phase 1b/2a clinical trial for the treatment of primary membranous nephropathy (pMN) with EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor will be presented in a focused oral session at the 62nd Congress of the European Renal Association (ERA 2025). Preliminary results showed that EVER001 was well-tolerated and effective in patients with pMN. These results support the potential of EVER001 as a treatment for proteinuric autoimmune glomerular diseases. This initial unveiling of the preliminary data at an international congress focuses on pMN, which is the second most common cause of primary glomerulonephritis. EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of autoimmune renal diseases. Compared to covalent irreversible BTK inhibitors, EVER001 offers improved selectivity while maintaining high potency, thereby potentially avoiding many of the side effects associated with earlier-generation BTK inhibitors. Everest Medicines holds global rights to EVER001 for the treatment of renal diseases. This oral presentation highlights an ongoing Phase 1b/2a clinical trial of EVER001 for the treatment of pMN, which is being conducted in China. The study is designed to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of EVER001 in Chinese patients with glomerular diseases characterized by proteinuria. A total of 31 patients with biopsy-proven pMN who tested positive for anti-PLA2R autoantibodies were enrolled into two cohorts. The total treatment duration was 36 weeks. The presentation includes longer-term data collected from some patients (10 patients in the low-dose cohort completed 52 weeks of follow-up, and 10 patients in the high-dose cohort completed 24 weeks of treatment). Preliminary results showed that EVER001 was well-tolerated and effective in patients with pMN. These results support the potential of EVER001 as a treatment for proteinuric autoimmune glomerular diseases. The trial results, based on data analysis as of December 17th, 2024, demonstrated that EVER001 was generally safe and well tolerated, with the most common TRAEs being Grade 1-2. No clinically significant adverse events commonly associated with covalent irreversible BTK inhibitors, such as bleeding, arrhythmia, severe infections, or severe liver function impairment were observed. Compared to baseline, the least squares (LS) geometric mean levels of anti-PLA2R autoantibodies decreased by 62.1% in the low-dose cohort and 87.3% in the high-dose cohort at week 12. The reductions in both cohorts reached approximately 93% at week 24. 76.9% of patients in the low-dose cohort and 81.8% in the high-dose cohort achieved immunological complete remission at week 24. For 24-hour proteinuria, the LS geometric mean decreased by 78.0% from baseline in the low-dose cohort at week 36 and the reduction was maintained for 16 weeks after the end of treatment. At week 36, 69.2% of patients in the low-dose group achieved clinical remission. In the high-dose cohort, proteinuria had already decreased by 70.1% at week 24, with 80.0% of patients achieving clinical remission. Patients in both cohorts maintained stable renal function during the treatment period. "As a next-generation BTK inhibitor, EVER001 offers key advantages, including covalent reversibility, high selectivity, strong target-binding affinity, and reduced off-target toxicity. These attributes highlight its substantial potential in the treatment of pMN." Professor Minghui Zhao, leading principal investigator of EVER001 and an influential nephrologist at Peking University First Hospital, said: "Preliminary results from the Phase 1b/2a clinical trial of EVER001, presented at the 62nd ERA Congress, demonstrate that EVER001 induced rapid reductions in anti-PLA2R autoantibodies and proteinuria observed across both low- dose and high-dose cohorts. The treatment exhibits a favorable safety and tolerability profile. Currently, no drug has been approved globally for the treatment of pMN. Traditional immunosuppressive therapies carry a high risk of relapse following discontinuation, and many are associated with adverse effects. We therefore hope that new treatment options will become available to offer patients safer and more effective therapies." "To date, no drug has been approved globally for the treatment of pMN. As a potential best-in-class therapy, EVER001 holds promise to offer more treatment options for over 10 million patients worldwide affected by pMN, IgA nephropathy (IgAN), minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and lupus nephritis (LN)." Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, said: "We are very pleased to see that the positive results in the preliminary analysis of our Phase 1b/2a clinical proof-of-concept trial of EVER001 were presented for the first time at an international academic conference. These preliminary results, disclosed at the 62nd ERA Congress, demonstrated that this next-generation covalent reversible BTK inhibitor was well-tolerated and effective in patients with pMN. Moving forward, we will continue to drive the global clinical development of EVER001, to meet patients' urgent clinical needs." pMN is a common pathological type of nephrotic syndrome in adults, and its prevalence in China has been increasing, ranking second only to IgA nephropathy[1]. There are approximately 2 million patients with pMN in China, and nearly 220,000 patients in the United States, Europe and Japan. There are no approved drugs for this indication worldwide. The current treatment goal is to improve remission rates, reduce high relapse rates, and minimize the risk of chronic toxicity caused by currently available treatments. More than one-third of pMN patients still progress to end-stage renal disease under current standards of care. This Phase 1b/2a clinical trial was approved by the Center for Drug Evaluation of the National Medical Products Administration in September 2022 to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of EVER001 in Chinese patients with glomerular diseases characterized by proteinuria. About EVER001 EVER001 (previously known as XNW1011) is a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in development globally for the treatment of renal diseases. BTK is an essential component of the B-cell receptor signaling pathways that regulate the survival, activation, proliferation, and differentiation of B lymphocytes. Targeting BTK with small molecule inhibitors has been demonstrated to be an effective treatment option for B-cell lymphomas and autoimmune diseases. Under an exclusive licensing agreement with Sinovent Pharmaceuticals and SinoMab BioScience, Everest owns global rights to develop, produce and commercialize EVER001 for the treatment of renal diseases. About Everest Medicines Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company's core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at Forward-Looking Statements: This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. References: 1. Expert consensus on the application of rituximab in the treatment of membranous nephropathy, Chin J Intern Med, March 2022, Vol. 61, No. 3. View original content: SOURCE Everest Medicines Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
